Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 4/12/16  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Nicholas D.P. Cosford

Wrong Dr. Nicholas D.P. Cosford?

Professor

Phone: (858) ***-****  
Email: n***@***.org
Sanford-Burnham Medical Research Institute
10901 North Torrey Pines Road
La Jolla , California 92037
United States

Company Description: At Sanford-Burnham, we are dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. With operations...   more
Background

Employment History

Board Memberships and Affiliations

Education

  • Ph.D.
    Burnham Institute for Medical Research
64 Total References
Web References
Graduate School Faculty
www.sbpdiscovery.org [cached]
Nicholas Cosford, Ph.D.
Associate Director of Translational Research, NCI-Designated Cancer Center Professor, NCI-Designated Cancer Center
...
Dr. Cosford's laboratory uses medicinal chemistry, chemical biology, rational drug design and microfluidic approaches to develop small-molecule modulators of cell death, survival and growth signaling pathways, for use as novel therapeutic agents to treat cancer, neurodegenerative and psychiatric disorders, and orphan diseases.
Prof. Nicholas Cosford, ...
www.calasiapharma.com [cached]
Prof. Nicholas Cosford, PhD
Dr. Cosford is Professor at Sanford Burnham Medical Research Institute, La Jolla, California. His research is involved in investigating the interactions of small molecule compounds with therapeutically important proteins and cellular signaling pathways. One aspect of his research emphasizes the use of medicinal chemistry and chemical biology approaches to probe intracellular pathways that regulate cell survival and cell growth. Another area of active research is the development of synthetic chemistry methodology using microfluidic technology for the rapid synthesis of biologically active small molecules. Therapeutically, his group is primarily focused on the discovery and optimization of compounds that have the potential to treat cancer, CNS diseases and infectious diseases. He has more than 20 years of experience leading small-molecule drug discovery projects in the pharmaceutical industry. At Sibia Neurosciences and at Merck Research Laboratories he directed multidisciplinary research teams focused on small-molecule hit-to-lead optimization and was responsible for moving several lead compounds through to the clinical phase. Examples include taking a nicotinic receptor agonist (Altinicline, SIB-1508Y) from initiation of research through to Phase II clinical for PD; taking mGluR5 negative allosteric modulators from HTS hits through in vivo proof-of-concept to Phase I clinical (ongoing); and design, synthesis and optimization of an mGluR5 PET tracer clinical candidate; design, synthesis and optimization of an Akt allosteric inhibitor preclinical candidate. To date, he has published more than 55 peer reviewed scientific publications, has more than 30 issued patents, and more than 30 additional patent applications pending. In 2006 he received the FRAXA Research Foundation Award for Outstanding Contributions to Fragile X Research.
Graduate School Faculty
www.sanfordburnham.org [cached]
Nicholas Cosford, Ph.D.
Professor, NCI-Designated Cancer Center Cell Death and Survival Networks Program
Dr. Cosford's laboratory uses medicinal chemistry, chemical biology, rational drug design and microfluidic approaches to develop small-molecule modulators of cell death, survival and growth signaling pathways, for use as novel therapeutic agents to treat cancer, neurodegenerative and psychiatric disorders, and orphan diseases.
Talent
www.sanfordburnham.org [cached]
Nicholas Cosford, Ph.D.
Professor, NCI-Designated Cancer Center
...
Dr. Cosford's laboratory uses medicinal chemistry, chemical biology, rational drug design and microfluidic approaches to develop small-molecule modulators of cell death, survival and growth signaling pathways, for use as novel therapeutic agents to treat cancer, neurodegenerative and psychiatric disorders, and orphan diseases.
In the accompanying commentary, Allison ...
www.eurekalert.org [cached]
In the accompanying commentary, Allison Limpert and Nicholas Cosford of the Sanford Burnham Institute for Medical Research discus the potential benefits of EEAT2 modulation in treating neurodegenerative disease.
...
AUTHOR CONTACT: Nicholas Cosford Sanford Burnham Institute for Medical Research, San Diego, CA, USA Phone: (858) 795-5316; E-mail: ncosford@sanfordburnham.org
View this article at:http://www.jci.org/articles/view/74608?key=c8cc94ae5cd76270cd4b
Other People with the name "Cosford":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.